Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
V Vallon, SC Thomson - Nature Reviews Nephrology, 2017 - nature.com
Nature Reviews Nephrology, 2017•nature.com
Inhibitors of renal sodium/glucose cotransporter 2 (SGLT2) are new anti-hyperglycaemic
drugs that reduce proximal tubular glucose and sodium reabsorption. The Canagliflozin
Cardiovascular Assessment Study (CANVAS) Program is the second major trial to
demonstrate beneficial effects of SGLT2 inhibitors on the kidney and cardiovascular system
in patients with type 2 diabetes mellitus.
drugs that reduce proximal tubular glucose and sodium reabsorption. The Canagliflozin
Cardiovascular Assessment Study (CANVAS) Program is the second major trial to
demonstrate beneficial effects of SGLT2 inhibitors on the kidney and cardiovascular system
in patients with type 2 diabetes mellitus.
Inhibitors of renal sodium/glucose cotransporter 2 (SGLT2) are new anti-hyperglycaemic drugs that reduce proximal tubular glucose and sodium reabsorption. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program is the second major trial to demonstrate beneficial effects of SGLT2 inhibitors on the kidney and cardiovascular system in patients with type 2 diabetes mellitus.
nature.com